Chinese inflammatory disease biotech Connect Biopharma prices upsized US IPO at $17 high end

Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, raised $191 million by offering 11.3 million ADSs at $17, the high end of the range of $15 to $17. The company offered 1.9 million more ADSs than anticipated. At prRead More